SCHEMBL3711705

SCHEMBL3711705

CC(C)CC(C(=O)O)N(CCc1cncn1CCc1ccccc1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
ACE2 Q9BYF1 4/20 0.36
ACE P12821 3/20 0.36
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MMP1 P03956 3/20 0.34
MMP3 P08254 3/20 0.34
CNOT7 Q9UIV1 1/20 0.33
MMP2 P08253 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
HTT P42858 1/20 0.33
PLK1 P53350 1/20 0.33
NOS1 P29475 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3712781 0.86 CYP11B1 (0.41) CYP11B1CYP11B2ACE2ACEMMP1
SCHEMBL7381299 0.84 CYP11B1 (0.43) CYP11B1CYP11B2ACE2ACE
SCHEMBL3704205 0.83 CYP11B1 (0.42) CYP11B1CYP11B2ACE2ACE
SCHEMBL7375020 0.83 CYP11B1 (0.39) CYP11B1CYP11B2ACE2ACENOS1
SCHEMBL3715232 0.83 CYP11B1 (0.39) CYP11B1CYP11B2ACE2ACEKMT2A
SCHEMBL3710371 0.82 CYP11B1 (0.41) CYP11B1CYP11B2ACE2ACE
SCHEMBL3714337 0.82 CYP11B1 (0.41) CYP11B1CYP11B2ACE2ACE
SCHEMBL3681437 0.82 ACE2 (0.48) CYP11B1CYP11B2ACE2ACE
SCHEMBL3715181 0.82 ACE2 (0.43) CYP11B1CYP11B2ACE2ACE
SCHEMBL1656651 0.82 CYP11B1 (0.52) CYP11B1CYP11B2ACE2ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010093804-A1 ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS ORE PHARMACEUTICALS, INC. (US) 2010-08-19 WO claimed
JP-2002543120-A 2002-12-17 JP claimed
WO-2000066104-A9 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARM INC (US) 2002-08-29 WO claimed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO claimed
EP-1183019-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-03-06 EP claimed
WO-2000066104-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2000-11-09 WO claimed
EP-3717077-A1 METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) 2020-10-07 EP disclosed
WO-2000066104-A9 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARM INC (US) 2002-08-29 WO disclosed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO disclosed
EP-1183019-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-03-06 EP disclosed
WO-2000066104-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2000-11-09 WO disclosed